Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
The objectives of the course include the discussion of the gaps of knowledge, of evidence and of organization in the field of pulmonary arterial hypertension. The stakeholders roundtable facilitates the promotion of proposals for the future.
Cardiologists, pediatric cardiologists, pulmonologists, internal medicine, rheumatologists, registered nurses.
N. Galiè (IT), G. Simonneau (FR)
D. Badesch (USA), M.Beghetti (CH), A. El-Gazayerly (NL), G.Fischer (AT), A.Ghofrani (DE), S. Gibbs (UK), W. Gin-Sing (UK), D. Ivy (USA), N.Kim (USA), J. Newman (USA), W.Seeger (DE), O. Sitbon (FR), A. Torbicki (PL), R.Tuder (USA), JL Vachiery (BE), A.Vonk Noordegraaf (NL)
Session 1: N. Galiè - G. Simonneau08:50 - 09:00 Welcome and Introduction - G. Simonneau09:00 - 09:30 Pathology – R. Tuder09:30 - 10:00 Pathobiology – R. Tuder10:00 - 10:30 Genetics/Genomics – J. Newman11:00 - 11: 30 Definitions and Classifications - G. Simonneau11:30 - 12:00 Pathophysiology - A.Vonk Nordegraaf Session 2: S. Gibbs, O. Sitbon13:00 – 13:30 Epidemiology and registries – O. Sitbon13:30 – 14:00 Diagnosis and Prognosis – D. Badesch14:00 – 14:30 Therapy – Standard of care - N. Galiè14:30 – 15:00 Discussion
Session 3 JL. Vachiery, M. Beghetti
15:30 – 16:00 Therapy – Goals - O. Sitbon16:00 – 16:30 New Design and New Therapies – A. Ghofrani16:30 – 17:00 CTEPH – N Kim17:00 – 17:30 PH due to Left Heart Disease and Chronic Lung Disease – W. Seeger 17:30 – 18:00 Pediatric PH – D. Ivy
Session 4 – G 6 Meeting: A Torbicki, G. Fischer
09:00 – 09:30 Expectations from Patients – G. Fischer09:30 – 10:00 Expectation from Nurses – W. Gin-Sing
10:30 – 11:00 The expectations of the Regulatory AgenciesA. El Gazayerly11:00 – 11:30 The expectations of the Industry – M. Ianosev11:30 – 12:00 The expectations of healthcare providers -D. Ivy Session 5: N. Galiè - G. Simonneau
12:00–12:45 Roundtable discussion with invited representatives of healthcare providers and industry (M. Alison (Bayer), L. Varanese (Eli-Lilly), M. Ianosev (GSK), S. Teal (Pfizer), A.Maresta (Actelion), A. El Gazayerly 12:45 – 13:00 Summary of the meeting and perspectives N. Galiè
European Society of Cardiology
Les Templiers2035 Route des CollesCS 80179 BIOT
06903 Sophia Antipolis, FR